CSPC Ouyi Pharmaceutical Co., Ltd.
Clinical trials sponsored by CSPC Ouyi Pharmaceutical Co., Ltd., explained in plain language.
Pharmaceutical subsidiary of CSPC Group, developing drugs and generics.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a single injection of SYH2082 help tackle obesity? a first-in-human trial puts safety to the test. Results expected Sep 2026 (estimated)
- New triple therapy aims to tame type 2 diabetes Results expected Oct 2026 (estimated)
- New injection aims to ease pain after abdominal surgery Results expected Dec 2026 (estimated)
- New pill could help millions with stubborn high cholesterol Results expected Jun 2027 (estimated)
-
Can an experimental injection help people with obesity shed pounds?
Disease control Not yet recruitingResearchers are testing an experimental injection called SYH2069 in adults who are overweight or obese but do not have diabetes. The study compares the drug against a placebo over 28 weeks to see if it leads to meaningful weight loss. Participants receive either SYH2069 or a plac…
Phase 2 • Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a Once-Weekly shot tame type 2 diabetes blood sugar?
Disease control Not yet recruitingThis Phase 2 trial tests an investigational once-weekly injection called SYH2069 in adults with type 2 diabetes whose blood sugar is not well controlled by diet, exercise, or metformin alone. Researchers compare several doses of SYH2069 against a placebo and an existing diabetes …
Phase 2 • Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New pill could help millions with stubborn high cholesterol
Disease control Not yet recruitingThis phase 3 trial tests bempedoic acid, a daily pill, in 222 adults with high cholesterol that statins alone can't control. Participants take the drug or a placebo for 12 weeks while staying on their usual cholesterol meds. The main goal is to see how much LDL ('bad') cholestero…
Phase 3 • Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC